To explore the clinical significance of YAP1 expression in NSCLC patients with acquired resistance to osimertinib, we further detected the expression levels of YAP1 protein in the tissues of NSCLC patients before and after osimertinib resistance. Here, YAP1 is linked to non-small cell lung carcinoma.